Get the Stockscreener App
1.795
1.99%
0.035
Ocugen Inc stock is traded at $1.795, with a volume of 6.39M.
It is up +1.99% in the last 24 hours and up +74.27% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.76
Open:
$1.79
24h Volume:
6.39M
Relative Volume:
1.55
Market Cap:
$524.69M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-6.6481
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
+6.85%
1M Performance:
+74.27%
6M Performance:
+208.00%
1Y Performance:
+87.33%
1-Day Range:
$1.765
$1.88
1-Week Range:
$1.645
$1.90
52-Week Range:
$0.515
$1.90
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.795 | 549.66M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.75 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
455.91 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
566.58 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.79 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
352.41 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen, Inc. Hits New 52-Week High of $1.90, Marking Major Milestone - Markets Mojo
Ocugen to Highlight Gene Therapy Pipeline at Key Industry and Investor Conferences - MyChesCo
Published on: 2025-10-06 02:02:01 - newser.com
Automated trading signals detected on Ocugen Inc.Market Rally & Weekly Breakout Opportunity Watchlist - newser.com
Analyzing recovery setups for Ocugen Inc. investorsJuly 2025 WrapUp & Free Daily Entry Point Trade Alerts - newser.com
Real time pattern detection on Ocugen Inc. stockFed Meeting & Smart Money Movement Alerts - newser.com
Published on: 2025-10-05 03:08:53 - newser.com
What drives Ocugen Inc 2H51 stock priceBull Market Opportunities & Explosive Growth Opportunities - earlytimes.in
Is Ocugen Inc 2H51 a good long term investmentPrice Volatility Patterns & You’ll Regret Not Buying These Early - earlytimes.in
Ocugen (NASDAQ:OCGN) Hits New 52-Week HighHere's Why - MarketBeat
Published on: 2025-10-03 06:57:10 - newser.com
How Ocugen Inc. (2H51) stock moves on employment dataQuarterly Earnings Report & AI Based Buy/Sell Signal Reports - newser.com
Can Ocugen Inc. (2H51) stock sustain double digit ROE2025 Market Trends & Long-Term Growth Stock Strategies - newser.com
Regression analysis insights on Ocugen Inc. performanceTrade Volume Report & Low Risk High Reward Ideas - newser.com
How to recover losses in Ocugen Inc. stockGap Down & Entry and Exit Point Strategies - newser.com
Will Ocugen Inc. stock outperform international peers2025 Institutional Moves & Verified Entry Point Signals - newser.com
Published on: 2025-10-03 02:54:41 - newser.com
Ocugen, Inc. to Present at NobleCon20 Emerging Growth Equity Conference - MSN
Ocugen to Present at Major Biotechnology Conferences Focused on Advancements in Gene Therapies for Blindness Diseases - Quiver Quantitative
Ocugen to Present at Industry and Investor Conferences in October 2025 - GlobeNewswire
Targeting 3 BLA Submissions: Ocugen Leadership to Present Gene Therapy Vision at Major Industry Events - Stock Titan
Traders Buy High Volume of Ocugen Call Options (NASDAQ:OCGN) - MarketBeat
Ocugen Inc Stock Analysis and ForecastInsider Selling Patterns & High Return Capital Gains - earlytimes.in
Ocugen Strikes $7.5 Million Licensing Deal With Kwangdong for Gene Therapy in Korea - MSN
Ocugen, Inc. Hits New 52-Week High of $1.69, Marking Significant Milestone - Markets Mojo
Moving Out on the Risk Curve With a Small-Cap Biotech Play - TheStreet Pro
Ocugen Receives FDA Greenlight for Phase 1 Trial of Mucosal COVID-19 Vaccine - MSN
Published on: 2025-09-27 15:47:02 - newser.com
User - FinancialContent
Goldman Sachs Group Inc. Lowers Holdings in Ocugen, Inc. $OCGN - MarketBeat
Ocugen Inc 2H51 Stock Analysis and ForecastBullish Engulfing Patterns & Free Discover Massive Upside Stocks - Early Times
Ocugen at H.C. Wainwright: Progress in Gene Therapy for Blindness - Investing.com
Ocugen at H.C. Wainwright: Progress in Gene Therapy for Blindness By Investing.com - Investing.com Canada
Ocugen, Inc. Hits New 52-Week High of $1.32, Marking Significant Milestone - Markets Mojo
Ocugen, Inc. Hits New 52-Week High of $1.48, Signaling Strong Momentum - Markets Mojo
Ocugen, Inc. Hits New 52-Week High at $1.78, Marking Significant Milestone - Markets Mojo
Ocugen (NASDAQ:OCGN) Reaches New 52-Week HighTime to Buy? - MarketBeat
Ocugen Shares Surge as Strategic Shift Renews Investor Confidence - AD HOC NEWS
200,100 Shares in Ocugen, Inc. $OCGN Acquired by Procyon Advisors LLC - MarketBeat
Ocugen's (OCGN) Buy Rating Reaffirmed at Chardan Capital - MarketBeat
Ocugen reports positive data for OCU400, OCU410 - MSN
Ocugen (NASDAQ:OCGN) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Ocugen: A Retinal Disease Juggernaut In The Making (NASDAQ:OCGN) - Seeking Alpha
Ocugen Strikes $187.5 Million Licensing Deal With Kwangdong for Gene Therapy in Korea - MSN
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.67%
4.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):